163 related articles for article (PubMed ID: 12529673)
21. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.
Frankel A; Liu JS; Rizzieri D; Hogge D
Leuk Lymphoma; 2008 Mar; 49(3):543-53. PubMed ID: 18297533
[TBL] [Abstract][Full Text] [Related]
22. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
Feuring-Buske M; Frankel A; Gerhard B; Hogge D
Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161
[TBL] [Abstract][Full Text] [Related]
23. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.
Feuring-Buske M; Gerhard B; Cashman J; Humphries RK; Eaves CJ; Hogge DE
Leukemia; 2003 Apr; 17(4):760-3. PubMed ID: 12682634
[TBL] [Abstract][Full Text] [Related]
24. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias.
Frankel AE; McCubrey JA; Miller MS; Delatte S; Ramage J; Kiser M; Kucera GL; Alexander RL; Beran M; Tagge EP; Kreitman RJ; Hogge DE
Leukemia; 2000 Apr; 14(4):576-85. PubMed ID: 10764142
[TBL] [Abstract][Full Text] [Related]
25. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
Rossi HA; O'Donnell J; Sarcinelli F; Stewart FM; Quesenberry PJ; Becker PS
Leukemia; 2002 Mar; 16(3):310-5. PubMed ID: 11896533
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
[TBL] [Abstract][Full Text] [Related]
28. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor.
Bendel AE; Shao Y; Davies SM; Warman B; Yang CH; Waddick KG; Uckun FM; Perentesis JP
Leuk Lymphoma; 1997 Apr; 25(3-4):257-70. PubMed ID: 9168436
[TBL] [Abstract][Full Text] [Related]
29. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins.
Jedema I; Barge RM; Frankel AE; Willemze R; Falkenburg JH
Exp Hematol; 2004 Feb; 32(2):188-94. PubMed ID: 15102480
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
[TBL] [Abstract][Full Text] [Related]
31. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells.
Kim CN; Bhalla K; Kreitman RJ; Willingham MC; Hall P; Tagge EP; Jia T; Frankel AE
Leuk Res; 1999 Jun; 23(6):527-38. PubMed ID: 10374846
[TBL] [Abstract][Full Text] [Related]
32. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor.
Frankel AE; Ramage J; Kiser M; Alexander R; Kucera G; Miller MS
Protein Eng; 2000 Aug; 13(8):575-81. PubMed ID: 10964987
[TBL] [Abstract][Full Text] [Related]
33. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
34. Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias.
Perentesis JP; Bendel AE; Shao Y; Warman B; Davies SM; Yang CH; Chandan-Langlie M; Waddick KG; Uckun FM
Leuk Lymphoma; 1997 Apr; 25(3-4):247-56. PubMed ID: 9168435
[TBL] [Abstract][Full Text] [Related]
35. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Perentesis JP; Waddick KG; Bendel AE; Shao Y; Warman BE; Chandan-Langlie M; Uckun FM
Clin Cancer Res; 1997 Mar; 3(3):347-55. PubMed ID: 9815691
[TBL] [Abstract][Full Text] [Related]
36. The majority of children and adolescents with acute myeloid leukemia have detectable anti-DT388-GMCSF IgG concentrations, but at concentrations that should not preclude in vivo activity.
Hall PD; Razzouk BI; Willoughby TE; McLean TW; Frankel AE
J Pediatr Hematol Oncol; 2002 Oct; 24(7):521-6. PubMed ID: 12368687
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
[TBL] [Abstract][Full Text] [Related]
38. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
[TBL] [Abstract][Full Text] [Related]
39. Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice.
Vallera DA; Seo SY; Panoskaltsis-Mortari A; Griffin JD; Blazar BR
Protein Eng; 1999 Sep; 12(9):779-85. PubMed ID: 10506288
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.
Breistøl K; Balzarini J; Sandvold ML; Myhren F; Martinsen M; De Clercq E; Fodstad O
Cancer Res; 1999 Jun; 59(12):2944-9. PubMed ID: 10383159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
